Abeer Arain

Dr. Abeer Arain

Houston Methodist Hospital
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Journal of Immunotherapy
Verified
Journal Article
Open access
EBEthan Burns
Ethan Burns
IMIbrahim N. Muhsen
Ibrahim N. Muhsen
Kartik AnandKartik Anand
Kartik Anand
JXJiaqiong Xu
Jiaqiong Xu
GUGodsfavour Umoru
Godsfavour Umoru
Maen AbdelrahimMaen Abdelrahim
Maen Abdelrahim
There have been unique adverse events reported with targeted blockade of programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA4), including immune mediated toxicities. Recently, there have been reports of hepatitis B reactivation (HBVr) occurring with PD-1/PD-L1 inhibitors, which may result in treatment delays, interruptions, or discontinuation. This retrospective literature review and analysis of the Food and Drug Administration’s (FDA) Adverse Events Reporting System (FAERS) queried reported cases of “Hepatitis B reactivation” reported with the PD-1/PD-L1 inhibitors “Pembrolizumab,” “Atezolizumab,” “Nivolumab,” “Durvalumab,” “Avelumab,” and “Ipilimumab” from initial FDA approval to June 30, 2020. Disproportionality signal analysis was determined by calculating a reporting odds ratio (ROR) and 95% confidence intervals (CI). The ROR was considered significant when the lower and upper limits of the 95% CI were >1 and confirmed by the Fisher exact test (P<0.05). Pembrolizumab had a strong signal associated with HBVr, with a ROR of 2.32 (95% CI: 1.11–4.28) (P=0.013) and was the only statistically significant finding. There were no reports of HBVr with Ipilimumab or Avelumab. Additional prospective studies should be conducted to validate the findings of this retrospective pharmacovigilance analysis to determine the risk of HBVr in patients receiving immune checkpoint inhibitors.

21 August 2014 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Closed access
PDF file
CMChance Matthiesen
Chance Matthiesen
THTania De La Fuente Herman
Tania De La Fuente Herman
HSHardev Singh
Hardev Singh
AMAnthony Mascia
Anthony Mascia
MCMichael Confer
Michael Confer
SASalahuddin Ahmad
Salahuddin Ahmad

1 July 2019 in Hematology/Oncology and Stem Cell Therapy
Verified
Journal Article
Open access
AAAbeer Arain
Abeer Arain
CMChance Matthiesen
Chance Matthiesen
Vitamins are the organic compounds that have long been known to play a significant role in our body by functioning as hormones and antioxidants. Vitamin D, a fat-soluble vitamin, is the main regulator of calcium hemostasis in our body. At the same time, it is also known to show its potential effects on the immune system by modulating the differentiation, activation, and proliferation of T and B lymphocytes. The immunomodulatory properties of vitamin D are also known to have a crucial role in the prevention and treatment of graft-versus-host disease. Patients undergoing hematopoietic stem cell transplantation are particularly at risk of vitamin D deficiency. This review article expands our understanding of vitamin D, its immunomodulatory effects, and its role in prevention and treatment of graft-versus-host disease.

26 November 2019 in Kansas Journal of Medicine
Verified
Journal Article
Open access
PDF file
AAAbeer Arain
Abeer Arain
MRMehmoodur Rasheed
Mehmoodur Rasheed
NSNader Sallam
Nader Sallam
ZSZoona Sarwar
Zoona Sarwar
MKMehwish Khan
Mehwish Khan
Introduction We evaluated the knowledge of non-steroidal antiinflammatory drugs (NSAIDs) including their dosage, side effects, contraindications, and drug interactions among the patients in an outpatient rheumatology clinic. Methods Patients in a rheumatology clinic completed a short survey assessing their knowledge of over-the-counter NSAIDs. Results The survey was provided to 400 participants and 275 (68.5%) were using over-the-counter (OTC) NSAIDs. The majority of the participants identified their commonly used NSAID. Almost a third were unaware of the contraindication of NSAIDs such as peptic ulcer disease, chronic kidney disease, and hypertension. Nearly 53.9% participants denied having any discussion of OTC medications with their providers. Two-thirds of the respondents reported seeing only the medication packaging for the dose determination (67.8%). Conclusions The gap in patient knowledge of the potential side effects and the lack of discussion of OTC medications by the providers may be predisposing the patients to preventable side effects from NSAIDs.

17 September 2018 in Chronic Diseases and Translational Medicine
Verified
Journal Article
Open access
PDF file
MAManushi Aggarwal
Manushi Aggarwal
AAAbeer Arain
Abeer Arain
Zhaohui JinZhaohui Jin
Zhaohui Jin
Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.

1 April 2015
Verified
Journal Article
Closed access
AAAbeer Arain
Abeer Arain
THTerence Herman
Terence Herman
CMChance Matthiesen
Chance Matthiesen